nintedanib DPI nintedanib Updated Aug 24
Watch for Phase 2 INFLO-2 enrollment completion updates and eventual topline efficacy data (likely 12-18 months out). For MNKD overall, the approved Afrezza and Furoscix franchises are nearer-term value drivers; nintedanib DPI is a pipeline optionality play. MannKind's analyst consensus is Strong Buy (12 Buy/Strong Buy vs 2 Hold) with a mean price target of $7.97 (84% upside from ~$4.07), but the stock also shows elevated short-volume ratios, indicating debate.
- Phase 1b INFLO-1 data showed a clean safety profile with zero serious adverse events, zero drug-related GI side effects, zero bronchospasm, zero discontinuations, and only mild/transient cough, directly addressing oral nintedanib's biggest weakness (GI intolerance which causes ~20-30% discontinuation rates).
- The Technosphere DPI platform is already validated through two FDA-approved products (Afrezza insulin, Furoscix), reducing formulation/device risk vs. a novel platform.
- The global IPF market is large and growing (oral nintedanib/Ofev is a ~$3B+ franchise for Boehringer Ingelheim) and an inhaled version that improves tolerability could capture significant share or expand the treated population.
- Phase 2 INFLO-2 efficacy data (FVC decline rate) has not yet been tested, positive safety does not guarantee efficacy. Inhaled nintedanib must demonstrate it reaches therapeutic concentrations in lung tissue.
- Avalyn Pharma (AVLN, IPO April 2026) is developing inhaled nintedanib (AP02) and inhaled pirfenidone (AP01) for the same IPF indication, with a ~$300M IPO war chest to fund Phase 2b/3 trials, direct competition.
- Oral nintedanib (Ofev by Boehringer Ingelheim) is deeply entrenched as standard-of-care for IPF; physician inertia and payer dynamics may slow inhaled adoption even if approved.